	US 12,240,894 B2
	Methods of treating AL amyloidosis
Gene Kinney, Boca Raton, FL (US); Wagner Marcelo Zago, San Carlos, CA (US); Carol Karp, Hillsborough, CA (US); and Radhika Tripuraneni, Menlo Park, CA (US)
Assigned to Prothena Biosciences Limited, Dublin (IE)
Filed by Prothena Biosciences Limited, Dublin (IE)
Filed on May 8, 2023, as Appl. No. 18/313,792.
Application 18/313,792 is a continuation of application No. 16/810,319, filed on Mar. 5, 2020, granted, now 11,692,024.
Claims priority of provisional application 62/942,722, filed on Dec. 2, 2019.
Claims priority of provisional application 62/814,252, filed on Mar. 5, 2019.
Prior Publication US 2023/0331831 A1, Oct. 19, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/18 (2006.01); A61B 5/00 (2006.01); A61B 5/0205 (2006.01); A61B 5/029 (2006.01); A61K 9/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61B 5/11 (2006.01)

CPC C07K 16/18 (2013.01) [A61B 5/0205 (2013.01); A61B 5/4839 (2013.01); A61B 5/4842 (2013.01); A61K 9/0019 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61B 5/029 (2013.01); A61B 5/1124 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01)]

25 Claims

1. A method of treating a patient having AL amyloidosis, comprising:

(a) selecting a patient having AL amyloidosis for treatment, if the patient has:

(i) Mayo Stage IV AL amyloidosis;

(ii) a 6 minute walk distance (6MWD)≥150 meters and an ejection fraction (EF)>50% at baseline;

(iii) Mayo Stage IV AL amyloidosis and an EF>50% at baseline; or

(iv) Mayo Stage IV AL amyloidosis, a 6MWD≥150 meters, and an EF>50% at baseline; and

(b) administering an effective dosage of an antibody to the selected patient, wherein the antibody comprises a light chain comprising the amino acid sequence set forth as SEQ ID NO: 10, and a heavy chain comprising the amino acid sequence set forth as SEQ ID NO: 12.